Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AssigneesThe Trustees of the University of Pennsylvania, Novartis AG
InventorsMichael C. Milone, Enxiu Wang
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
Claims23
A purified, or non-naturally occurring, activating killer cell immunoglobulin-like receptor chimeric antigen receptor (actKIR-CAR) comprising:
- an extra-cellular antigen binding domain from an antibody molecule or a non-antibody scaffold;
- an activating killer cell immunoglobulin-like receptor (actKIR) transmembrane domain;
- and
- a cytoplasmic domain.
Dependencies are inferred from the claim text.